Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice
- 1 September 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (9) , 1629-1632
- https://doi.org/10.1128/aac.34.9.1629
Abstract
Disseminated Mycobacterium avium infection is the major cause of bacteremia in patients with acquired immunodeficiency syndrome. We present here a new animal model of this disease, thymectomized C57BL/6 mice that were intravenously infused with monoclonal antibody to selectively deplete CD4+ T cells. The increased susceptibility of such animals to M. avium infection is comparable to that of C57BL/6 beige mice and thus may provide a viable alternative to the latter model. Further, using representative strains of acquired immunodeficiency syndrome-associated M. avium (serotypes 1, 4, and 8 and a rough isolate), we show that the course of such infections in thymectomized, CD4-deficient mice can be markedly restrained and in some cases the infections can be sterilized by treatment over a 120-day period with a regimen containing 40 mg of the new antimycobacterial agent rifabutin per kg (body weight).This publication has 16 references indexed in Scilit:
- Mycobacteria and AIDS MortalityAmerican Review of Respiratory Disease, 1989
- Antimycobacterial ActivityIn Vivoof LM427 (Rifabutin)American Review of Respiratory Disease, 1988
- Susceptibility ofMycobacterium aviumComplex to Various Two-drug Combinations of Antituberculosis AgentsAmerican Review of Respiratory Disease, 1988
- In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige miceAntimicrobial Agents and Chemotherapy, 1988
- Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndromeAntimicrobial Agents and Chemotherapy, 1988
- Mycobacterium avium Complex InfectionThe Journal of Infectious Diseases, 1988
- An Acute Infection Model forMycobacterium intracellulareDisease Using Beige Mice: Preliminary Results1,2American Review of Respiratory Disease, 1983
- In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complexAntimicrobial Agents and Chemotherapy, 1982
- The beige mutation in the mouse selectively impairs natural killer cell functionNature, 1979